Weeks after bowing out of a billion-dollar deal with Aduro Biotech, J&J is back to the drawing board with another oncology licensing pact that, if fruitful, could pit them directly against AstraZeneca’s lung cancer star Tagrisso.
Korean drugmaker Yuhan is collecting $50 million upfront on the deal, which centers around lazertinib, a third-generation EGFR tyrosine-kinase inhibitor designed to target multiple mutations of the receptor. With worldwide rights to the asset — except for South Korea — J&J will take over development, manufacturing and commercialization while collaborating with Yuhan on clinical trials.
Yuhan could rake in another $1.205 billion on potential milestones, along with “tiered double-digit royalties.”
For an idea of the market opportunity that J&J has in mind, one needs look further than Tagrisso, the third-gen EGFR-TKI that AstraZeneca execs have talked up as a $3 billion drug considering its recent approval as a frontline treatment of EGFR-mutated non-small cell lung cancer.
In fact, when Yuhan and its partner Genosco presented “highly encouraging” Phase I/II data at ASCO this year, the principal investigator said the results “indicate that lazertinib compares favorably with results from a similar Phase 1/2 clinical trial of osimertinib,” or Tagrisso.
The results, Yuhan now says, points to lazertinib’s potential as a first-line therapy and “a potential best-in-class candidate as a combination regimen.”
J&J will now get to work in pursuit of that potential. Both monotherapy and combo trials are slated to begin in 2019.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,100+ biopharma pros who read Endpoints News by email every day.Free Subscription